Literature DB >> 21109772

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes.

C R Giver, D L Jaye, E K Waller, J L Kaufman, S Lonial.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21109772     DOI： 10.1038/leu.2010.262

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

Authors:  U Platzbecker; H K Al-Ali; N Gattermann; D Haase; V Janzen; J Krauter; K Götze; R Schlenk; F Nolte; A Letsch; O G Ottmann; A Kündgen; M Lübbert; U Germing; M Wermke; H Reinhard; C Weiss; K Lieder; G Ehninger; O Leismann; A Giagounidis
Journal:  Leukemia       Date:  2013-11-04       Impact factor: 11.528

2.  Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.

Authors:  Camelia Iancu-Rubin; David Gajzer; Goar Mosoyan; Faye Feller; John Mascarenhas; Ronald Hoffman
Journal:  Exp Hematol       Date:  2012-02-27       Impact factor: 3.084

3.  Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.

Authors:  John H Strickler; Alexander N Starodub; Jingquan Jia; Kellen L Meadows; Andrew B Nixon; Andrew Dellinger; Michael A Morse; Hope E Uronis; P Kelly Marcom; S Yousuf Zafar; Sherri T Haley; Herbert I Hurwitz
Journal:  Cancer Chemother Pharmacol       Date:  2012-06-29       Impact factor: 3.333

4.  Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.

Authors:  Sachi Morita; Satoshi Oizumi; Hironobu Minami; Koichi Kitagawa; Yoshito Komatsu; Yutaka Fujiwara; Megumi Inada; Satoshi Yuki; Naomi Kiyota; Ayako Mitsuma; Masataka Sawaki; Hiromi Tanii; Junko Kimura; Yuichi Ando
Journal:  Invest New Drugs       Date:  2011-10-01       Impact factor: 3.850

5.  Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.

Authors:  Quentin Chalret du Rieu; Sylvain Fouliard; Anne Jacquet-Bescond; Renata Robert; Ioana Kloos; Stéphane Depil; Etienne Chatelut; Marylore Chenel
Journal:  Pharm Res       Date:  2013-06-05       Impact factor: 4.200

6.  Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.

Authors:  Paul G Richardson; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw W Jedrzejczak; Andreas Guenther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Robert L Schlossman; Jian Hou; Philippe Moreau; Sagar Lonial; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Bourras-Rezki Bengoudifa; Claudia Corrado; Florence Binlich; Jesús F San-Miguel
Journal:  Blood       Date:  2015-12-02       Impact factor: 22.113

Review 7.  Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.

Authors:  Avineesh Singh; Vijay K Patel; Deepak K Jain; Preeti Patel; Harish Rajak
Journal:  Oncol Ther       Date:  2016-06-10

8.  Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Authors:  Jonathan L Kaufman; Roberto Mina; Andrzej J Jakubowiak; Todd L Zimmerman; Jeffrey J Wolf; Colleen Lewis; Charise Gleason; Cathy Sharp; Thomas Martin; Leonard T Heffner; Ajay K Nooka; R Donald Harvey; Sagar Lonial
Journal:  Blood Cancer J       Date:  2019-01-04       Impact factor: 11.037

Review 9.  The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.

Authors:  Jesus F San-Miguel; Hermann Einsele; Philippe Moreau
Journal:  Adv Ther       Date:  2016-09-27       Impact factor: 3.845
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.